Skip to Content

Myozyme Approval History

  • FDA approved: Yes (First approved April 28th, 2006)
  • Brand name: Myozyme
  • Generic name: alglucosidase alfa
  • Company: Genzyme Corp.
  • Treatment for: Pompe disease

Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder.

Development History and FDA Approval Process for Myozyme

Apr 28, 2006Approval Myozyme Approved - Genzyme Corp. - Treatment for Pompe Disease
Jan 17, 2006Genzyme Provides Update on U.S. Marketing Application for Myozyme
Jul 29, 2005Genzyme Submits BLA for Myozyme for Treatment of Pompe Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.